Loading...

Inovio Pharmaceuticals

DB:GBMB
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GBMB
DB
$365M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. The last earnings update was 40 days ago. More info.


Add to Portfolio Compare Print
  • Inovio Pharmaceuticals has significant price volatility in the past 3 months.
GBMB Share Price and Events
7 Day Returns
-9.3%
DB:GBMB
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-12.5%
DB:GBMB
-10.2%
DE Biotechs
-6%
DE Market
GBMB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Inovio Pharmaceuticals (GBMB) -9.3% 1.1% -26.6% -12.5% -63.5% -53.6%
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • GBMB underperformed the Biotechs industry which returned -10.2% over the past year.
  • GBMB underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
GBMB
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Inovio Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Inovio Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €3.246.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Inovio Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Inovio Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:GBMB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.05
NasdaqGS:INO Share Price ** NasdaqGS (2019-04-18) in USD $3.73
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Inovio Pharmaceuticals.

DB:GBMB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:INO Share Price ÷ EPS (both in USD)

= 3.73 ÷ -1.05

-3.56x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Inovio Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Inovio Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Inovio Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:GBMB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.56x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
25%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Inovio Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Inovio Pharmaceuticals's assets?
Raw Data
DB:GBMB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.89
NasdaqGS:INO Share Price * NasdaqGS (2019-04-18) in USD $3.73
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:GBMB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:INO Share Price ÷ Book Value per Share (both in USD)

= 3.73 ÷ 0.89

4.17x

* Primary Listing of Inovio Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Inovio Pharmaceuticals is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Inovio Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Inovio Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Inovio Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
25%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Inovio Pharmaceuticals expected to grow at an attractive rate?
  • Inovio Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Inovio Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Inovio Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:GBMB Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:GBMB Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 25%
DB:GBMB Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 46.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:GBMB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:GBMB Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 214 44 5
2022-12-31 116 -52 5
2021-12-31 30 -118 5
2020-12-31 14 -116 5
2019-12-31 32 -95 5
DB:GBMB Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 30 -74 -97
2018-09-30 37 -70 -86
2018-06-30 37 -63 -95
2018-03-31 33 -61 -97
2017-12-31 42 -63 -88
2017-09-30 42 -64 -93
2017-06-30 52 -65 -80
2017-03-31 38 -62 -89
2016-12-31 35 -63 -74
2016-09-30 33 -54 -65
2016-06-30 44 -20 -39
2016-03-31 44 -16 -27

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Inovio Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Inovio Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:GBMB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Inovio Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GBMB Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.34 0.59 0.17 4.00
2022-12-31 -0.43 -0.02 -0.75 5.00
2021-12-31 -1.06 -0.82 -1.27 5.00
2020-12-31 -1.11 -0.93 -1.23 7.00
2019-12-31 -0.97 -0.56 -1.27 7.00
DB:GBMB Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.05
2018-09-30 -0.94
2018-06-30 -1.05
2018-03-31 -1.14
2017-12-31 -1.08
2017-09-30 -1.20
2017-06-30 -1.07
2017-03-31 -1.20
2016-12-31 -1.01
2016-09-30 -0.90
2016-06-30 -0.54
2016-03-31 -0.37

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Inovio Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Inovio Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Inovio Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Inovio Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Inovio Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Inovio Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Inovio Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Inovio Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Inovio Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Inovio Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GBMB Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 30.48 -96.97 29.32
2018-09-30 36.77 -85.51 31.71
2018-06-30 37.41 -94.63 31.24
2018-03-31 33.37 -97.47 30.22
2017-12-31 42.22 -88.21 28.29
2017-09-30 41.95 -92.93 27.22
2017-06-30 51.84 -79.56 26.66
2017-03-31 37.63 -88.78 26.29
2016-12-31 35.37 -73.74 23.89
2016-09-30 32.79 -65.46 21.79
2016-06-30 44.43 -39.11 20.41
2016-03-31 43.52 -26.65 19.33
2015-12-31 40.57 -29.19 18.06
2015-09-30 37.09 -18.65 17.43
2015-06-30 14.75 -31.42 16.20
2015-03-31 13.27 -35.88 15.83
2014-12-31 10.46 -36.12 15.86
2014-09-30 9.74 -44.16 15.97
2014-06-30 17.39 -67.86 16.10
2014-03-31 14.37 -68.01 14.80
2013-12-31 13.47 -66.03 13.64
2013-09-30 12.86 -51.23 12.22
2013-06-30 4.23 -26.98 11.61
2013-03-31 3.88 -20.26 11.26
2012-12-31 4.12 -19.67 10.78
2012-09-30 4.62 -24.49 11.54
2012-06-30 6.40 -22.41 11.19

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Inovio Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Inovio Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Inovio Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Inovio Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Inovio Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Inovio Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Inovio Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Inovio Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Inovio Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Inovio Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Inovio Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Inovio Pharmaceuticals Company Filings, last reported 3 months ago.

DB:GBMB Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 87.03 0.00 81.23
2018-09-30 103.71 0.00 85.49
2018-06-30 111.49 0.00 95.60
2018-03-31 113.09 0.00 112.77
2017-12-31 142.49 0.00 127.43
2017-09-30 162.12 0.00 141.89
2017-06-30 123.53 0.00 92.00
2017-03-31 105.95 0.00 89.66
2016-12-31 123.38 0.00 104.77
2016-09-30 146.98 0.00 119.69
2016-06-30 162.09 0.00 134.53
2016-03-31 171.22 0.00 146.79
2015-12-31 175.93 0.00 162.99
2015-09-30 193.39 0.00 170.78
2015-06-30 180.96 0.00 154.59
2015-03-31 103.43 0.00 81.01
2014-12-31 111.54 0.00 93.62
2014-09-30 117.04 0.00 100.93
2014-06-30 122.27 0.00 108.86
2014-03-31 129.18 0.00 116.78
2013-12-31 52.90 0.00 52.63
2013-09-30 62.22 0.00 46.17
2013-06-30 29.67 0.00 23.46
2013-03-31 40.42 0.00 28.07
2012-12-31 34.86 0.00 13.68
2012-09-30 31.28 0.00 15.14
2012-06-30 36.36 0.00 19.44
  • Inovio Pharmaceuticals has no debt.
  • Inovio Pharmaceuticals has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Inovio Pharmaceuticals has sufficient cash runway for 1.1 years based on current free cash flow.
  • Inovio Pharmaceuticals has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 33.2% each year.
X
Financial health checks
We assess Inovio Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Inovio Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Inovio Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Inovio Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Inovio Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Inovio Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Inovio Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:GBMB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:GBMB Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Inovio Pharmaceuticals has not reported any payouts.
  • Unable to verify if Inovio Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Inovio Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Inovio Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Inovio Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Inovio Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Inovio Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Inovio Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Inovio Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
J. Kim
COMPENSATION $3,081,043
AGE 49
TENURE AS CEO 9.8 years
CEO Bio

Dr. J. Joseph Kim, Ph.D has been the Chief Executive Officer of Inovio Pharmaceuticals, Inc. (alternate name: Inovio Biomedical Corp) since June 1, 2009 and has been its President since October 6, 2009. Dr. Kim co-founded ADViSYS Inc., a subsidiary of Viral Genomix in 1997 and served as its Chief Executive Officer and President. He co-founded VGX Pharmaceuticals, LLC (Formerly Viral Genomix, Inc) in 2000 and served as its Chief Executive Officer and President from 2000 to June 1, 2009. Dr. Kim is a veteran of the biopharmaceutical industry. Dr. Kim joined VGX Pharmaceuticals from Merck & Co. He has over 10 years of experience in the field of biopharmaceuticals, with a focus on drug and vaccine development. He serves as the Chairman of VGX Animal Health, Inc. He has been Director of Inovio Biomedical Corp since June 1, 2009. He served as Director of ADViSYS Inc. Dr. Kim served as Director of VGX Pharmaceuticals, LLC from 2000 to June 1, 2009. In 2002, Dr. Kim has been named one of the world’s top 100 young innovators by Technology Review magazine. The “TR100”, as this group is called was chosen by a very distinguished Panel of Judges (which includes 2 Nobel Prize Laureates). Recently, he has been selected for the “40 under 40” by the Philadelphia Business Journal as one of the 40 most dynamic professionals who are under 40 years of age in the region. Dr. Kim was also selected on the list of the “50 Most Influential Men“ in the October 2003 and in the October 2006 “Power Issue“ of Details Magazine. He was featured in the “Who's Next 2005“ issue of Newsweek International. In 2006, Dr. Kim has been named a Young Global Leader by the Forum of Young Global Leaders, an affiliate of the World Economic Forum. He was among 175 leading executives, public figures and intellectuals under the age of 40 from 50 countries. Dr. Kim has been a Director at Inovio Pharmaceuticals, Inc. since June 1, 2009. Dr. Kim is a veteran of the biopharmaceutical industry. He was trained in economics, engineering and biological sciences at MIT where he was a Robert C. Byrd Federal Honors Scholar. Dr. Kim holds a Ph.D. in Biochemical Engineering from the University of Pennsylvania and an MBA in Finance from the Wharton School.

CEO Compensation
  • J.'s compensation has been consistent with company performance over the past year.
  • J.'s remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Inovio Pharmaceuticals management team in years:

1.3
Average Tenure
51.5
Average Age
  • The average tenure for the Inovio Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

J. Kim

TITLE
CEO, President & Director
COMPENSATION
$3M
AGE
49
TENURE
9.8 yrs

Peter Kies

TITLE
Chief Financial Officer
COMPENSATION
$1M
AGE
55
TENURE
16.8 yrs

Jacqueline Shea

TITLE
COO & Executive VP
AGE
52
TENURE
0.1 yrs

Laurent Humeau

TITLE
Chief Scientific Officer & Executive VP
AGE
51
TENURE
0.4 yrs

Ben Matone

TITLE
Director of Investor Relations
TENURE
1.3 yrs

E. Brandreth

TITLE
Senior Vice President of Quality Assurance

Jessica Lee

TITLE
Senior Vice President of Clinical Operations & Global Integration

Ami Brown

TITLE
Senior Vice President of Regulatory Affairs

Stephen Kemmerrer

TITLE
Senior Vice President of Engineering Development

Kate Broderick

TITLE
Senior Vice President of Research & Development
Board of Directors Tenure

Average tenure and age of the Inovio Pharmaceuticals board of directors in years:

7
Average Tenure
62.5
Average Age
  • The tenure for the Inovio Pharmaceuticals board of directors is about average.
Board of Directors

Simon Benito

TITLE
Chairman of Board of Directors
COMPENSATION
$151K
AGE
73
TENURE
0.3 yrs

J. Kim

TITLE
CEO, President & Director
COMPENSATION
$3M
AGE
49
TENURE
9.8 yrs

David Weiner

TITLE
Chairman of the Scientific Advisory Board & Director
COMPENSATION
$448K
AGE
62
TENURE
19.3 yrs

Angel Cabrera

TITLE
Director
COMPENSATION
$137K
AGE
50
TENURE
6.8 yrs

Wendy Yarno

TITLE
Director
COMPENSATION
$139K
AGE
63
TENURE
1.3 yrs

Stanley Plotkin

TITLE
Member of Scientific Advisory Board
AGE
85
TENURE
9.8 yrs

Mort Collins

TITLE
Director
COMPENSATION
$140K
AGE
82
TENURE
9.8 yrs

Tony Ford-Hutchinson

TITLE
Member of Scientific Advisory Board
TENURE
7.1 yrs

Rafi Ahmed

TITLE
Member of Scientific Advisory Board
TENURE
0.4 yrs

Lota Zoth

TITLE
Director
AGE
58
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
11. Jul 18 Sell Peter Kies Individual 09. Jul 18 10. Jul 18 -20,000 €3.79 €-75,711
X
Management checks
We assess Inovio Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Inovio Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system’s tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical studies of its proprietary SynCon immunotherapies for human papillomavirus-caused pre-cancers and cancers; bladder cancer; glioblastoma multiforme; hepatitis B virus; hepatitis C virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include MedImmune, Limited; The Wistar Institute; University of Pennsylvania; GeneOne Life Science Inc.; ApolloBio Corporation; Regeneron Pharmaceuticals, Inc.; Genentech, Inc.; Plumbline Life Sciences, Inc.; Drexel University; National Institute of Allergy and Infectious Diseases; United States Military HIV Research Program; U.S. Army Medical Research Institute of Infectious Diseases; National Institutes of Health; HIV Vaccines Trial Network; Defense Advanced Research Projects Agency; the Parker Institute for Cancer Immunotherapy; and Coalition for Epidemic Preparedness Innovations. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Details
Name: Inovio Pharmaceuticals, Inc.
GBMB
Exchange: DB
Founded: 1979
$324,819,298
97,934,010
Website: http://www.inovio.com
Address: Inovio Pharmaceuticals, Inc.
660 West Germantown Pike,
Suite 110,
Plymouth Meeting,
Pennsylvania, 19462,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS INO Common Stock Nasdaq Global Select US USD 01. May 1992
DB GBMB Common Stock Deutsche Boerse AG DE EUR 01. May 1992
Number of employees
Current staff
Staff numbers
281
Inovio Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:20
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/18
Last earnings filing: 2019/03/12
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.